Maximum Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography and Glucose Transporter-1 Expression Correlates With Survival in Invasive Ductal Carcinoma of the Pancreas

Kitasato, Yuhei; Yasunaga, Masafumi; Okuda, K; Kinoshita, Hisafumi; Tanaka, Hiroyuki; Okabe, Yoshinobu; Kawahara, Akihiko; Kage, Masayoshi; Kaida, Hayato; Ishibashi, Masatoshi

doi:10.1097/mpa.0000000000000185

Cited by 34 publications

(18 citation statements)

References 25 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are mixed reports on the utility of FDG-PET compared with CT, MRI, and endoscopic ultrasound techniques. The most useful aspect of FDG-PET for PDAC appears to be the strong correlation between levels of FDG uptake and tumor aggressiveness in terms of pathological grade (Ahn et al, 2014;Chen et al, 2016), prediction of distant metastasis (Shinoto et al, 2013), and survival (Chen et al, 2016;Kitasato et al, 2014;Lee et al, 2014;Yamamoto et al, 2015). The strongest critique against use of FDG-PET in PDAC is the observation that it is no more effective than conventional imaging techniques to diagnose early stage pancreatic cancer or to detect small metastases (Matsumoto et al, 2013;Rijkers et al, 2014).…”

Section: Metabolic Imagingmentioning

confidence: 99%

Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer

2017

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is on pace to become the second leading cause of cancer-related death. The high mortality rate results from a lack of methods for early detection and the inability to successfully treat patients once diagnosed. Pancreatic cancer cells have extensively reprogrammed metabolism, which is driven by oncogene-mediated cell-autonomous pathways, the unique physiology of the tumor microenvironment, and interactions with non-cancer cells. In this review, we discuss how recent efforts delineating rewired metabolic networks in pancreatic cancer have revealed new in-roads to develop detection and treatment strategies for this dreadful disease.

show abstract

Section: Metabolic Imagingmentioning

confidence: 99%

Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer

2017

View full text Add to dashboard Cite

show abstract

“…Measurement of steady state metabolite levels suggests that glucose concentrations are not significantly elevated in most PDAs compared to adjacent pancreatic tissue (29). Nevertheless, among PDAs, higher levels of glucose uptake and expression of the primary glucose transporter, GLUT1 (SLC21A), correlate with worse prognosis (41, 42). Moreover, alterations in glucose delivery and utilization are required for PDA tumorigenesis, and mutant KRAS serves as a major regulator of these processes.…”

Section: Glucose and Glutamine Metabolism In Pdamentioning

confidence: 99%

Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up

2015

View full text Add to dashboard Cite

How do cancer cells escape tightly controlled regulatory circuits that link their proliferation to extracellular nutrient cues? An emerging theme in cancer biology is the hijacking of normal stress response mechanisms to enable growth even when nutrients are limiting. Pancreatic ductal adenocarcinoma (PDA) is the quintessential aggressive malignancy that thrives in nutrient-poor, hypoxic environments. PDAs overcome these limitations through appropriation of unorthodox strategies for fuel source acquisition and utilization. Additionally, interplay between evolving PDA and whole body metabolism contributes to disease pathogenesis. Deciphering how these pathways function and integrate with one another can reveal novel angles of therapeutic attack.

show abstract

“…SUVmax in pancreatic cancer and non-small cell lung cancer (NSCLC), in which EGFR and P53 mutations are associated with tumor progression or chemotherapy resistance (16,17). Besides, several studies have reported the relationship between the SUVmax and some serum tumor biomarker levels in many kinds of cancers, such as CA19-9, CA72-4, and CEA (18)(19)(20).…”

Section: Suvmax Of 18 F-fdg Pet/ct Correlates To Expression Of Major mentioning

confidence: 99%

SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients

et al. 2017

View full text Add to dashboard Cite

The expression of P53 was previously found by us significantly correlated with maximal standardized uptake value (SUVmax) in non-small cell lung cancer (NSCLC) patients. Hence, the aim of this study was to clarify the relationship between SUVmax and the status of the chemotherapy-related tumor marker expression or serum tumor markers in gastric adenocarcinoma patients. Sixty-four gastric adenocarcinoma patients who underwent 18F-FDG PET/CT prior to treatment were enrolled in this study. Immunohistochemistry was performed to detect changes of Her-2, P53 and Survivin in lesions, and electrochemiluminescence (ECL) method was used to quantify expression of serum CA72-4, CA19-9 and CEA of these patients. Then, the relationships between these parameters above were assessed by Spearman correlation analysis. Also, receiver-operating characteristic (ROC) curve was performed to determine the best cut-off value of SUVmax for suggesting chemotherapy resistant tumor markers. Besides, we identified a linear correlation to estimate the equations between SUVmax and the serum tumor markers. Our results showed that higher SUVmax was detected in patients with positive expression of Her-2 and P53, compared with negative groups. The Spearman correlation analysis showed that SUVmax was associated with Her-2 or P53 with the moderate relevant Pearson correlation coefficient. ROC curve analysis showed that the sensitivity and specificity of SUVmax for suggesting Her-2 or P53-positive, when the cut-off value of SUVmax was set at 3.25 or 5.45, respectively. Moreover, the relationship between SUVmax and serum tumor markers were analyzed by linear correlation analysis, and serum CA72-4 and CA19-9 could be used as independent parameters to establish an equation for SUVmax by the linear regression models. These results suggested that SUVmax of 18F-FDG PET/CT could be used to predict and evaluate Her-2 or P53 related chemotherapy resistance of gastric adenocarcinoma patients. However, before PET/CT scanning, serum tumor markers could be used to calculate the SUVmax approximately.

show abstract

Maximum Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography and Glucose Transporter-1 Expression Correlates With Survival in Invasive Ductal Carcinoma of the Pancreas

Cited by 34 publications

References 25 publications

Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer

Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic Cancer

Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up

SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients

Contact Info

Product

Resources

About